Nimbus Therapeutics Secures $210M Financing Following $6B TYK2 Asset Sale to Advance Next-Generation Small Molecule Pipeline

On September 6, Nimbus Therapeutics, a clinical-stage company that designs and develops breakthrough drugs through its powerful computational drug discovery engine, announced the completion of a $210 million financing round to advance the next wave of small-molecule drug development based on its proprietary technology platform.

This round of financing was co-led by new investor GV (Google Ventures), existing investor SR One, and Atlas Venture.GatesFrontier、PfizerVentures and RA Capital Management, among other existing investors, as well as another new fund, participated in the investment.

Nimbus Therapeutics will continue the clinical development of NDI-101150, an HPK1 inhibitor for patients with solid tumors. Additionally, new funding will advance multiple preclinical programs into and through early clinical development, including programs targeting WRN (Werner syndrome helicase) and an undisclosed autoimmune disease target. Nimbus is also collaborating with Eli Lilly and Company to develop novel targeted therapies that treat a potentially broad range of metabolic disorders by activating AMPK. (Recommended reading:)

Nimbus Therapeutics, Inc. was founded in 2009 and is headquartered in Boston, Massachusetts. The company focuses on developing small-molecule drugs targeting hard-to-drug targets based on structural design. Its previous financing performance has been consistently impressive, with cumulative fundraising reaching nearly $700 million to date. Over the past four years, the company has successfully completed new financing rounds annually, completely unaffected by the capital winter.

The Financing History of Nimbus Therapeutics (Source: )

NimbusCombining advanced computational techniques with a series of machine learning-based predictive modeling methodsThe current pipeline includes an HPK1 inhibitor in clinical stage (NCT05128487), as well as a portfolio of various preclinical programs for the treatment of cancer, autoimmune diseases, and metabolic disorders.

Source: Nimbus Therapeutics Official Website

NimbusGained global attention in December last year due to a deal with Takeda.On December 13, 2022, Takeda announced the acquisition of Nimbus Lakshmi, a wholly-owned subsidiary of Nimbus Therapeutics, and its Tyrosine Kinase 2 (TYK2) inhibitor NDI-034858. NDI-034858 is an oral, selective allosteric TYK2 inhibitor that succeeded in a Phase IIb trial for psoriasis and is being evaluated for the treatment of various autoimmune diseases.

According to the terms of the agreement, Nimbus Therapeutics will receive an upfront payment of $4 billion from the deal, along with up to $2 billion in sales milestones.A Drug with a Potential Total Benefit of $6 Billion, showing MNC's great recognition of Nimbus. On February 8 this year, Nimbus Therapeutics announced that the transaction had been completed.

After NDI-034858, can Nimbus' platform still produce such a significant molecule?From the latest financing, well-known investment institutions (including Google Ventures, Bill Gates' fund, Pfizer Ventures, etc.) have expressed their stance, believing in the further potential of Nimbus Therapeutics.

"Nimbus CEO Jeb Keiper said, 'With the support of top-tier investors, along with the company's robust pipeline and unparalleled team, Nimbus is moving into its next chapter.'"

Dr. Bruce Booth (Source: Nimbus Therapeutics Official Website)

"The ability of Nimbus to repeatedly design and develop differentiated, clinically validated small-molecule drugs is a strong testament to the strength of its team and structure-based drug design platform. We believe the new financing will drive the emergence of the next breakthrough drug in Nimbus' portfolio," said Dr. Bruce Booth, Partner at Atlas Venture, Chairman and Co-founder of Nimbus.

References:

[1]https://www.nimbustx.com/2023/09/06/nimbus-therapeutics-secures-210m-private-financing-to-advance-next-wave-of-tech-enabled-small-molecule-medicines/

[2]https://www.nimbustx.com/2022/12/13/takeda-to-acquire-nimbus-therapeutics-highly-selective-allosteric-tyk2-inhibitor-to-address-multiple-immune-mediated-diseases/

[3]https://www.nimbustx.com/2023/02/08/nimbus-therapeutics-announces-closing-of-takedas-acquisition-of-tyk2-subsidiary/

Copyright © 2023 PHARMCUBE. All Rights Reserved.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article; if you need to reprint, please leave a message to the WeChat Official Account's backend or send a message, and specify the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and cannot be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.

Exciting Preview

Online Live Streaming & Offline Salon